|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Patients with BRAF (v-Raf murine sarcoma viral oncogene homolog B) V600E-mutated metastatic colorectal cancer (mCRC) have a poor prognosis.
|
30662270 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
|
31840683 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A combination of encorafenib, cetuximab, and binimetinib resulted in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the <i>BRAF</i> V600E mutation.
|
31566309 |
2019 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
|
28972961 |
2017 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis.
|
26460303 |
2015 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These data suggest that combined therapy with RAF and EGFR inhibitors could be an effective strategy for treating BRAF V600E mCRC.
|
25589621 |
2015 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
By calculating the ΔC q for real-time traditional PCR, which amplifies all BRAF alleles, versus WTB-PCR, which selectively amplifies mutant BRAF, we demonstrated that among the V600E-positive mCRC patient samples, the percentage of BRAF DNA with the V600E mutation ranged from 0.05 to 52.32%.
|
24500755 |
2014 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study aimed to evaluate the relationship between BRAF V600E mutation and the tumor response of anti-EGFR MoAbs for first-line treatment in mCRC patients.
|
24390240 |
2014 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we report the first clinical evidence that the combination of an anti-EGFR (panitumumab) and an inhibitor of BRAF(V600E) (vemurafenib) is well tolerated and results in a strong disease control in an extensively pretreated mCRC patient.
|
24755613 |
2014 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be either a complementary or an alternative method to molecular testing in mCRC patients.
|
24798160 |
2014 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
|
21289333 |
2011 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In this study, 239 samples obtained from 215 patients with metastatic colorectal cancer were tested for the presence of the seven most common mutations in the KRAS gene and the V600E mutation in the BRAF gene.
|
20645028 |
2011 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, large-scale KRAS mutation screening is needed for efficient patient management and in the future metastatic colorectal cancer genotyping might also include the detection of the BRAF V600E mutation, which is a very strong negative prognostic factor in colorectal cancer.
|
21516079 |
2011 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis provides evidence that BRAF V600E mutation is associated with lack of response in wild-type KRAS mCRC treated with anti-EGFR MoAbs.
|
20857202 |
2011 |
|
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
ICECREAM is a randomised, phase II, open-label, controlled trial comparing the efficacy of cetuximab alone or with irinotecan in patients with "quadruple wild type" or G13D-mutated metastatic colorectal cancer, whose disease has progressed on, or who are intolerant of oxaliplatin- and fluoropyrimidine-based chemotherapy.
|
27246726 |
2016 |
|
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This meta-analysis demonstrates no significant difference between KRAS G13D and other KRAS MT tumours in terms of treatment benefit from anti-EGFR mAbs for mCRC.
|
26812186 |
2016 |
|
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan.
|
27114605 |
2016 |
|
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab.
|
22537608 |
2012 |
|
rs909797662
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
|
20978259 |
2010 |
|
rs144460286
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using a system of paired NRAS-mutant and wild-type isogenic mCRC cell lines to explore signaling pathways engaged by the common oncogenic NRAS Q61K variant upon challenge with cetuximab, we uncovered an unexpected mechanism of resistance to cetuximab involving dysregulation of the ephrin-A1/EphA2 signaling axis.
|
28560458 |
2017 |
|
rs144460286
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using isogenic mCRC cells with a heterozygous knock-in of the NRAS activating mutation Q61K, we aimed to elucidate the mechanism(s) by which mutant NRAS blocks cetuximab from inhibiting mCRC growth.
|
27636997 |
2016 |
|
rs2227983
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Four EGFR polymorphisms (-216, -191, CA-SSR, R521K) were analysed in 51 patients with mCRC receiving anti-EGFR.
|
25039761 |
2014 |